<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00952848</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000644516</org_study_id>
    <secondary_id>MCV-MCC-12110</secondary_id>
    <nct_id>NCT00952848</nct_id>
  </id_info>
  <brief_title>Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy</brief_title>
  <official_title>The Efficacy of MC5-A (&quot;Scrambler&quot;) Therapy in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Phase II Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Electronic stimulation using a MC5-A Scrambler may help relieve pain in patients
      who develop peripheral neuropathy while undergoing chemotherapy treatments for cancer.

      PURPOSE: This phase II trial is studying how well MC5-A Scrambler therapy works in reducing
      peripheral neuropathy caused by chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine if MC5-A Scrambler therapy will improve the pain associated with
           chemotherapy-induced peripheral neuropathy in cancer patients by 20%.

      Secondary

        -  To evaluate the effect of MC5-A therapy on specific pain and neuropathy scales.

        -  To evaluate the effect of MC5-A therapy on overall quality of life.

        -  To evaluate the effect of MC5-A therapy on other pain drugs used.

        -  To evaluate the toxicities of MC5-A therapy.

      OUTLINE: Patients undergo gel electrode application on the skin in the most pain-free of the
      pain-affected area. Patients undergo treatment with the MC5-A Scrambler machine over 60
      minutes once daily on days 1-10. On day 1, the treatment intensity is increased every 10
      minutes to the maximum intensity individually bearable by the patient without any input of
      pain or discomfort. The patient should feel the disappearance of the pain during treatment as
      a sign that the proper nerve pathway(s) has (have) been correctly identified. Subsequent
      treatments begin at the highest intensity tolerated at the previous treatment. Patients with
      no improvement after 3 treatments discontinue treatment.

      Patients complete questionnaires about symptoms, pain, and quality of life periodically.

      After completion of study treatment, patients are followed up at 2 and 4 weeks, monthly for 3
      months, and at 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 12, 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Score</measure>
    <time_frame>15 days</time_frame>
    <description>Change in Neumeric Rating Score for Pain as measured by a Numeric Pain Rating scale between day 0 to day 15.
Scale is 0 (none) to 10 (severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of MC5-A on Pain and Neuropathy</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change on pain and neuropathy as measured by the Eastern Cooperative Oncology Group (ECOG) Common Toxicity Criteria for Sensory Neuropathy scale,0=none to 4=paralysis; the World Health Organization (WHO) Classification Scale, 0=none to 4=paralysis; and the Brief Pain Inventory-Short Form, 0=none to 4=most intense pain imaginable. Scores will be averaged.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of MC5-A on Morphine Oral Equivalent Doses Used Before and After MC5-A Therapy</measure>
    <time_frame>2 weeks</time_frame>
    <description>The change in overal equivalent doses (all narcotic doses will be converted to morphine oral equivalent doses ie as mg/24hours. (All opiates taken will be recorded for the full 24 hours preceding the visit or phone call. All opiates will be converted to the pnmorphine equivalent using the Morphine oral dose equivalents (MOED). The total MOEDs taken during the 24 hours will be the sum of all opiates taken) used before intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of MC5-A Therapy on Global Quality of Life Using the Uniscale Instrument</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change on global quality of life. The global quality of life will improve as measured by the Uniscale Linear Analog Scale Assessment (LASA) quality of life scale 0=as bad as it can be to 10=as good as it can be. Scores will be averaged.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Chemotherapeutic Agent Toxicity</condition>
  <condition>Neurotoxicity</condition>
  <condition>Pain</condition>
  <condition>Peripheral Neuropathy</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>MC5-A Scramble instrument</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of chronic neuropathic pain with the MC5-A device</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Pain Rating Score</description>
    <arm_group_label>MC5-A Scramble instrument</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sensory Neuropathy Scale instrument</intervention_name>
    <description>ECOG Common Toxicity Criteria for Sensory Neuropathy scale</description>
    <arm_group_label>MC5-A Scramble instrument</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of Life instrument</intervention_name>
    <description>Uniscale 0-100 scale global quality of life</description>
    <arm_group_label>MC5-A Scramble instrument</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MC5-A Scrambler device</intervention_name>
    <description>Electrical stimulation for 60 minutes</description>
    <arm_group_label>MC5-A Scramble instrument</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Chemotherapy-induced peripheral neuropathy (CIPN) meeting the following criteria:

               -  More than 4 weeks since prior neurotoxic chemotherapy including taxanes (e.g.,
                  paclitaxel or docetaxel), platinum-based compounds (e.g., carboplatin,
                  cis-platinum, oxaliplatin), vinca-alkaloids (e.g., vincristine, vinblastine, or
                  vinorelbine), or proteosome inhibitors (e.g., bortezomib)

               -  Pain or symptoms of peripheral neuropathy for ≥ 1 month attributed to CIPN

               -  Pain stable for ≥ 2 weeks

               -  Average daily pain rating of ≥ 5 out of 10 using the pain numerical rating scale
                  (0 is no pain and 10 is worst pain possible)

          -  No symptomatic brain metastases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 3 months

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No history of an allergic reaction or intolerance to transcutaneous electronic nerve
             stimulation

          -  No pacemaker or implantable drug-delivery system (e.g., Medtronic Synchromed)

          -  No heart stent or vena cava clips

          -  No history of epilepsy or brain damage

          -  No other identified causes of painful paresthesias existing before chemotherapy (e.g.,
             radiation or malignant plexopathy, lumbar or cervical radiculopathy, pre-existing
             peripheral neuropathy of another etiology [e.g., B12 deficiency, AIDS, monoclonal
             gammopathy, diabetes, heavy metal poisoning amyloidosis, syphilis, hyperthyroidism,
             hypothyroidism, inherited neuropathy, etc.])

          -  No skin conditions (e.g., open sores) that would prevent proper application of the
             electrodes

          -  No other medical or other conditions that, in the opinion of the investigators, might
             compromise the objectives of the study

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 30 days since prior and no concurrent investigational agents for pain control

          -  More than 4 weeks since prior and no concurrent celiac plexus block or other
             neurolytic pain control treatment

          -  No prior or concurrent anti-convulsants

          -  No concurrent neurotoxic or potentially neurotoxic chemotherapy

          -  Concurrent pain treatments allowed provided the following criteria are met:

               -  Pain is not satisfactorily controlled

               -  Dose of the other medication has been stable for ≥ 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J. Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <results_first_submitted>November 30, 2012</results_first_submitted>
  <results_first_submitted_qc>February 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 22, 2013</results_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>neurotoxicity</keyword>
  <keyword>chemotherapeutic agent toxicity</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>peripheral neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of recruitment: 06/12/2009 - 10/26/2009 Location of recruitment: medical clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>MC5-A Scrambler Instrument</title>
          <description>Treatment of chronic neuropathic pain with the MC5-A device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MC5-A Scrambler Instrument</title>
          <description>Treatment of chronic neuropathic pain with the MC5-A device</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Score</title>
        <description>Change in Neumeric Rating Score for Pain as measured by a Numeric Pain Rating scale between day 0 to day 15.
Scale is 0 (none) to 10 (severe)</description>
        <time_frame>15 days</time_frame>
        <population>Patients treated with MC5A devise for 10 consectuvive days</population>
        <group_list>
          <group group_id="O1">
            <title>MC5-A Pain Treatment Device</title>
            <description>Patients treated with the MC5-A device for chronic chemotherapy-induced peripheral neuropathy</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Score</title>
          <description>Change in Neumeric Rating Score for Pain as measured by a Numeric Pain Rating scale between day 0 to day 15.
Scale is 0 (none) to 10 (severe)</description>
          <population>Patients treated with MC5A devise for 10 consectuvive days</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="-3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of MC5-A on Pain and Neuropathy</title>
        <description>Change on pain and neuropathy as measured by the Eastern Cooperative Oncology Group (ECOG) Common Toxicity Criteria for Sensory Neuropathy scale,0=none to 4=paralysis; the World Health Organization (WHO) Classification Scale, 0=none to 4=paralysis; and the Brief Pain Inventory-Short Form, 0=none to 4=most intense pain imaginable. Scores will be averaged.</description>
        <time_frame>2 weeks</time_frame>
        <population>Patients treated with MC5A devise for 10 consectuvive days</population>
        <group_list>
          <group group_id="O1">
            <title>MC5-A Pain Treatment Device</title>
            <description>Patients treated with the MC5-A device for chronic chemotherapy-induced peripheral neuropathy</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of MC5-A on Pain and Neuropathy</title>
          <description>Change on pain and neuropathy as measured by the Eastern Cooperative Oncology Group (ECOG) Common Toxicity Criteria for Sensory Neuropathy scale,0=none to 4=paralysis; the World Health Organization (WHO) Classification Scale, 0=none to 4=paralysis; and the Brief Pain Inventory-Short Form, 0=none to 4=most intense pain imaginable. Scores will be averaged.</description>
          <population>Patients treated with MC5A devise for 10 consectuvive days</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.083" upper_limit="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of MC5-A on Morphine Oral Equivalent Doses Used Before and After MC5-A Therapy</title>
        <description>The change in overal equivalent doses (all narcotic doses will be converted to morphine oral equivalent doses ie as mg/24hours. (All opiates taken will be recorded for the full 24 hours preceding the visit or phone call. All opiates will be converted to the pnmorphine equivalent using the Morphine oral dose equivalents (MOED). The total MOEDs taken during the 24 hours will be the sum of all opiates taken) used before intervention</description>
        <time_frame>2 weeks</time_frame>
        <population>Patients treated with MC5A devise for 10 consectuvive days</population>
        <group_list>
          <group group_id="O1">
            <title>MC5-A Pain Treatment Device</title>
            <description>Patients treated with the MC5-A device for chronic chemotherapy-induced peripheral neuropathy</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of MC5-A on Morphine Oral Equivalent Doses Used Before and After MC5-A Therapy</title>
          <description>The change in overal equivalent doses (all narcotic doses will be converted to morphine oral equivalent doses ie as mg/24hours. (All opiates taken will be recorded for the full 24 hours preceding the visit or phone call. All opiates will be converted to the pnmorphine equivalent using the Morphine oral dose equivalents (MOED). The total MOEDs taken during the 24 hours will be the sum of all opiates taken) used before intervention</description>
          <population>Patients treated with MC5A devise for 10 consectuvive days</population>
          <units>mg/24hr</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.25" lower_limit="-45.38" upper_limit="-37.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity of MC5-A Therapy on Global Quality of Life Using the Uniscale Instrument</title>
        <description>Change on global quality of life. The global quality of life will improve as measured by the Uniscale Linear Analog Scale Assessment (LASA) quality of life scale 0=as bad as it can be to 10=as good as it can be. Scores will be averaged.</description>
        <time_frame>2 weeks</time_frame>
        <population>Patients treated with MC5A devise for 10 consectuvive days</population>
        <group_list>
          <group group_id="O1">
            <title>MC5-A Pain Treatment Device</title>
            <description>Patients treated with the MC5-A device for chronic chemotherapy-induced peripheral neuropathy</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity of MC5-A Therapy on Global Quality of Life Using the Uniscale Instrument</title>
          <description>Change on global quality of life. The global quality of life will improve as measured by the Uniscale Linear Analog Scale Assessment (LASA) quality of life scale 0=as bad as it can be to 10=as good as it can be. Scores will be averaged.</description>
          <population>Patients treated with MC5A devise for 10 consectuvive days</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MC5-A Scrambler Instrument</title>
          <description>Treatment of chronic neuropathic pain with the MC5-A device</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE v3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Unrelated to intervention.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas J. Smith, MD, FACP</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>410-955-2091</phone>
      <email>tsmit136@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

